Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Bearish flow noted in Biogen (BIIB) with 1,136 puts trading, or 1.1x expected. Most active are Apr-25 160 puts and 11/29 weekly 162.5 calls, ...

Biogen will face ongoing challenges as these expectations are ... Price Action: BIIB stock is down 1.15% at $158.15 at the ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

The firm has a market cap of $23.31 billion, a P/E ratio of 14.45, a P/E/G ratio of 1.51 and a beta of -0.06. The firm’s 50 ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

Today, Benzinga 's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of ...

Biogen stock fell 1.2% to 210.70. Shares are trading below their 50-day and 200-day lines, according to MarketSurge. Across all products, sales were flat at $2.47 billion. In constant currency ...

The $1.8 billion deal – which comes just weeks after Biogen chief executive Chris Viehbacher said the company wasn’t expecting to sign any large deals this year in its first-quarter results ...